ClinicalTrials.gg
RecruitingNCT07259278Updated Dec 2, 2025

Intelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients

An interventional study of AI-Enabled Stratified Management System and Usual post-discharge care in Secondary Prevention of Coronary Heart Disease, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases — 12 open to participants now, 13 under way, none of them phase 3. Coronary Disease · China National Center for Cardiovascular Diseases.

Planned enrollment
9th of 13
200 · median 240
Started
2025
with 5 others
No phase
7 of 25
5 open now
Primary completion
2026-11
later than 5 of 12 live
Registered
21st of 25
by date

Among the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases, this one is the 9th largest by planned enrollment of the 13 interventional ones that give a count, is one of 6 that started in 2025, is one of 7 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 21st registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

12 of the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases, or all of them as a file.
02

Study summary

The goal of this clinical trial is to find out if an artificial intelligence (AI)-enabled stratified management platform can help adults with coronary heart disease (CHD) better perform exercise rehabilitation and manage their health after being discharged from the hospital. The main questions it aims to answer are:

  1. Does using the AI platform lead to a greater improvement in exercise capacity (measured by peak oxygen consumption, VO2peak) after 3 months?
  2. Does the platform help increase daily physical activity, improve exercise adherence and motivation, and better control modifiable cardiovascular risk factors?
  3. Is guiding home-based exercise with this platform safe for low-risk CHD patients?

Researchers will compare the AI Management Group (using the platform and a sports wristband) to the Routine Management Group (receiving usual care without the platform) to see if the AI group shows more significant improvements in fitness and health metrics.

Participants will:

  1. Be randomly assigned to either use the AI platform or receive usual post-discharge care.
  2. Receive a personalized exercise prescription from a doctor before going home.
  3. If in the AI group: Use the smartphone app and wearable device to track health data for comprehensive post-discharge management, and receive reminders and immediate safety alerts.
  4. Attend a follow-up visit at 3 months for check-ups and tests, including an exercise test and health assessments.

The study hopes to show that this intelligent management platform is an effective and safe tool to help people with CHD recover at home, stay active, and reduce future heart risks.

03

Conditions studied

  • Secondary Prevention of Coronary Heart Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CHD patients aged over 18 years;
  • Stratified as low-risk for cardiovascular events during exercise and classified as low-risk according to the GRACE risk score.
  • Ability of the patient or close relatives to use smartphones and applications;
  • Willingness to participate and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Residual stenosis of >50% in the left main coronary artery, or >70% stenosis in other major epicardial vessels;
  • Planned coronary revascularization within the next 3 months;
  • Acute myocardial infarction within the past 1 month;
  • Severe cognitive impairment;
  • Severely impaired exercise capacity.
  • Advanced-stage ;
  • less than 3 months;
  • Severe multi-organ failure;
  • Other conditions deemed unsuitable for home-based exercise rehabilitation following assessment by a specialist rehabilitation physician.
  • Refusal to provide written .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    AI-Enabled Stratified Management Group

    Participants in the intervention group will receive comprehensive post-hospital rehabilitation management through an AI-based stratified management platform, utilizing a smartphone app and wearable device to track health data, deliver reminders and immediate safety alerts.

    Combination Product: AI-Enabled Stratified Management System · Combination Product: Usual post-discharge care

  • Active comparator
    Standard Post-Discharge Care Group

    Participants in the control group will receive usual discharge protocol and personalized exercise prescription and goals from a specialist.

    Combination Product: Usual post-discharge care

Interventions

  • Combination productAI-Enabled Stratified Management System

    Following discharge, participants in the AI-stratified management group will use an intelligent platform (smartphone app + wearable divice) for home-based exercise rehabilitation and comprehensive post-discharge care. Key features include: 1) Safety Monitoring \& Alerts: Real-time tracking of heart rate and other parameters via wristband triggers immediate safety warnings during exercise; 2) Holistic Risk Management: Integrated support for lifestyle modification, medication adherence, and control of cardiovascular risk factors; 3) Structured Engagement: Multi-channel reminders (messages, alarms, voice calls) for medications, exercise, and follow-ups to sustain adherence.

  • Combination productUsual post-discharge care

    Usual discharge protocol comprising verbal and printed discharge instructions addressing medication schedules, follow-up timelines, and lifestyle optimization strategies as well as a personalized exercise prescription.

06

What researchers measure

Primary outcomes

  1. Peak oxygen consumption (VO2peak)

    Peak oxygen consumption (VO2peak, mL∙kg-¹min-¹)

    Time frame: From enrollment to the end of treatment at 3 months.

Secondary outcomes

  1. Change in 6-minute walk distance

    6-minute walk distance (m)

    Time frame: From enrollment to the end of treatment at 3 months

  2. Change in physical activity level (MET-min/week)

    Physical activity level (MET-min/week), estimated using the International Physical Activity Questionnaire-Short Form (IPAQ-SF). It consists of 7 questions with a recall period defined as 'last week'. The questions of the scale ask whether the participant walks for at least 10 minutes on any given day or does moderate or vigorous activities, and how much time/day the individual spends on each of these activities or sit.

    Time frame: From enrollment to the end of treatment at 3 months

  3. Change in average daily step count

    Average daily step count (steps per day)

    Time frame: From enrollment to the end of treatment at 3 months

  4. Exercise adherence

    In the self-reported exercise diary, the participant will note the number of exercises done at home. The percentage adherence to the prescribed exercise regimen was calculated by dividing the number of exercises performed by the number of exercises prescribed and multiplying by 100.

    Time frame: From enrollment to the end of treatment at 3 months.

  5. Composite endpoints

    A composite endpoint including all-cause mortality, cardiac arrest, non-fatal myocardial infarction, and symptom-driven unplanned rehospitalization occurring during exercise. Safety endpoint during rehabilitation.

    Time frame: From enrollment to the end of treatment at 3 months

  6. Systolic blood pressure (mmHg)

    Systolic blood pressure. Unit of Measure: mmHg.

    Time frame: From enrollment to the end of treatment at 3 months

  7. Diastolic blood pressure (mmHg)

    Diastolic blood pressure. Unit of Measure: mmHg.

    Time frame: From enrollment to the end of treatment at 3 months

  8. Glycated hemoglobin (HbA1c, %)

    Glycated hemoglobin. Unit of Measure: %.

    Time frame: From enrollment to the end of treatment at 3 months

  9. Low-density lipoprotein cholesterol (LDL-C, mmol/L)

    Unit of Measure: mmol/L

    Time frame: From enrollment to the end of treatment at 3 months

  10. Body mass index (BMI, kg/m^2)

    Time frame: From enrollment to the end of treatment at 3 months

  11. Unplanned rehospitalization due to cardiovascular causes

    Time frame: From enrollment to the end of treatment at 3 months

  12. Major Adverse Cardiovascular Events (MACE)

    Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.

    Time frame: From enrollment to the end of treatment at 3 months

  13. Anxiety level by Generalized Anxiety Disorder-7 scale score

    Anxiety level, assessed using the Generalized Anxiety Disorder-7 (GAD-7) questionnaire. Patients will be evaluated at the beginning and at the endpoint of the study with the self-administered GAD-7 scale. The GAD-7 scale score ranges from 0 to 21 points. A score between 5 and 9 points characterizes mild GAD. Between 10 and 14, moderate GAD and between 15 and 21, severe GAD.

    Time frame: From enrollment to the end of treatment at 3 months

  14. Depression level by Patient Health Questionnaire-9 (PHQ-9)

    Depression level, assessed using the Patient Health Questionnaire-9 (PHQ-9). The GAD-7 scale score ranges from 0 to 27 points. A score between 5 and 9 points characterizes mild depression. Between 10 and 14, moderate depression; between 15 and 19, moderate-severe depression; and between 20 and 27, severe depression.

    Time frame: From enrollment to the end of treatment at 3 months

  15. Sleep quality, assessed using the Pittsburgh Sleep Quality Index (PSQI)

    Sleep quality, assessed using the Pittsburgh Sleep Quality Index (PSQI). The total score ranges from 0 to 21 with a higher score indicating poor quality of sleep (worse). The higher the score, the worse the sleep quality. A cut-off score of \>5 indicates poor sleep quality.

    Time frame: From enrollment to the end of treatment at 3 months

  16. Quality of life by the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire

    Quality of life, assessed using the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire. This questionnaire asks 5 multiple-choice questions about mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. EQ-5D-5L index scores range from 0 to 100, where 100 is the best possible health state.

    Time frame: From enrollment to the end of treatment at 3 months

07

Study locations

1 of 1 sites recruiting
  • Fuwai Hospital, Chinese Academy of Medical Sciences/National Center for Cardiovascular Diseases
    Beijing, Beijing Municipality 100037, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) that underlie the results reported in publications will be shared, including all collected de-identified IPD.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will be available beginning 6 months after publication of the primary results and will remain available for at least 5 years thereafter.

Access criteria: De-identified IPD and supporting documents will be made available upon reasonable request to the Principal Investigator (PI). Requests must include a methodologically sound proposal and intended use. Access will be granted at the discretion of the PI after review of the request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Nov 2026, 11 months later.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 11 months is below that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Dec 2, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07259278
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Dec 2, 2025

Study contacts

Prof. Gao, MD, PhD
Contact
sophie_gao@sina.com
010-88322413

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion